CAMP4 THERAPEUTICS CORPORATION
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $3.5M | $652.0K | $350.0K |
| Cost of Revenue | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin | — | — | — |
| Operating Expenses | |||
| Research & Development | $38.2M | $38.8M | $40.6M |
| SG&A Expense | $17.4M | $14.9M | $11.6M |
| Operating Income | $-52.6M | $-53.1M | $-51.9M |
| Operating Margin | -1,502.4% | -8,142.3% | -14,822.6% |
| Interest Expense | — | — | — |
| Pretax Income | — | — | — |
| Income Tax Expense | $0 | $0 | $0 |
| Net Income | $-80.4M | $-51.8M | $-49.3M |
| Net Margin | -2,298.5% | -7,943.4% | -14,083.1% |
| EPS (Basic) | $-2.65 | $-1.84 | $-1.73 |
| EPS (Diluted) | $-2.65 | $-1.84 | $-1.73 |
| Shares Outstanding (Basic) | 30.4M | 28.1M | 28.4M |
| Shares Outstanding (Diluted) | 30.4M | 28.1M | 28.4M |
| Dividends Per Share | $0.00 | $0.00 | — |